A36

A36 is a novel small molecule dual inhibitor of Bcr-Abl and Src kinases, primarily investigated for the treatment of chronic myeloid leukemia (CML). Developed by the Institute of Materia Medica at the Chinese Academy of Medical Sciences, A36 was designed to overcome resistance to first-generation tyrosine kinase inhibitors like imatinib. The compound works by competitively binding to the ATP-binding sites of both the Bcr-Abl fusion protein and members of the Src kinase family, thereby blocking downstream signaling pathways essential for leukemic cell proliferation and survival. Preclinical studies have demonstrated that A36 effectively induces apoptosis and cell cycle arrest in various CML cell lines, including those harboring certain imatinib-resistant mutations, although its clinical development status remains early-stage or discontinued.